CASE REPORT

Cutaneous lymphangitis carcinomatosa made cervicofacial oedema intractable in a patient with superior vena cava syndrome

Eriko Kashihara,1 Osamu Kanai,2 Misato Okamura,2 Tadashi Mio2

SUMMARY

Cutaneous lymphangitis carcinomatosa (CLC) is a rare form of cutaneous metastasis that causes lymphoedema and various eruptions. We report a case of lung cancer with CLC that caused both superior vena cava (SVC) stenosis and cervicofacial oedema, suggestive of SVC syndrome. A 64-year-old woman with lung adenocarcinoma presented with cervicofacial oedema and erythema, followed by severe dyspnoea 2 months after four cycles of carboplatin, pemetrexed and bevacizumab triplet therapy. Although chest CT indicated SVC stenosis, cervicofacial oedema remained despite treating the SVC stenosis via balloon dilation. A skin biopsy of the erythematic sample confirmed CLC as the cause of the patient's symptoms. CLC should be considered as a differential diagnosis of cervicofacial oedema in addition to SVC syndrome, especially when it is observed in combination with skin erythema and induration. Moreover, a skin biopsy should be performed promptly for accurate diagnosis of CLC and to decide on appropriate treatment.

BACKGROUND

When lung cancer progression causes symptoms that reduce the ability to manage daily activities, adequate symptom treatment is required. Superior vena cava (SVC) syndrome is a major complication of lung cancer that occurs when the lung tumour compresses the SVC extrinsically, which causes cervicofacial oedema and dyspnoea. Among treatment options for SVC syndrome, an indwelling SVC stent effectively improves symptoms within a few days. Cutaneous lymphangitis carcinomatosa (CLC), a rare condition that accounts for less than 5% of cutaneous metastases, also causes cervicofacial oedema, and patients with CLC usually present with progressive lymphoedema and erythema. Here, we report a rare case of lung adenocarcinoma with CLC and SVC stenosis in a patient whose cervicofacial oedema and dyspnoea remained despite improving SVC blood flow via balloon dilation.

CASE PRESENTATION

A 64-year-old woman with a 20-pack-year smoking history presented with a persistent cough for 3 months. Chest CT showed a 10 mm-diameter nodule in the right upper lobe of her lung and swelling of the supraclavicular, mediastinal and right hilar lymph nodes. Tissue samples obtained via mediastinoscopy indicated adenocarcinoma harbouring EGFR mutations: G719S (exon 18) and T790M (exon 20). Enhanced brain MRI showed frontal and occipital brain metastases. Thus, the patient was diagnosed with stage IV lung adenocarcinoma (cT1aN3M1b) based on the seventh edition of the Union for International Cancer Control Tumour–Node–Metastasis classification of Malignant Tumours. She achieved partial response after four cycles of carboplatin, pemetrexed and bevacizumab triplet therapy, which was discontinued due to drug-induced interstitial pneumonia.

Two weeks after the onset of drug-induced interstitial pneumonia, the patient developed prominent oedema and erythema in her neck and face, followed by dyspnoea (figure 1A,B). Contrast-enhanced CT revealed severe SVC stenosis, which suggested that the symptoms primarily resulted from SVC syndrome (figure 2). The patient underwent angiography and balloon dilation, after which SVC blood flow remained, despite prominent stenosis. Although the SVC was dilated by the procedure, cervicofacial oedema and dyspnoea improvement was observed for only a few hours. Chest CT performed the following day revealed that the SVC remained constricted, suggesting the existence of other causes that made the patient’s symptoms more intractable (figure 3).

Concomitantly, the patient developed painless erythema and induration of the chest and abdomen. Before angiography, a skin biopsy was performed at the erythematic site, which revealed neoplastic cells within the lumina of dermal lymphatic vessels and infiltration into the dermis and hypodermis (figure 4A). Immunohistochemistry staining revealed that the cells were positive for cytokeratin, thyroid transcription factor-1 and napsin A (figure 4B,C). From these results, we diagnosed the cause of oedema and dyspnoea of the patient as CLC and SVC syndrome.

OUTCOME AND FOLLOW-UP

The patient died of respiratory failure 1 week after CLC diagnosis.

DISCUSSION

We reported a case of lung adenocarcinoma with a combination of CLC and SVC stenosis, which presented with cervicofacial oedema and dyspnoea. Balloon dilation failed to improve these symptoms,
Reminder of important clinical lesson

In the present case, the patient presented with induration of the chest and abdomen, and a prompt skin biopsy confirmed the diagnosis of CLC. CLC is a rare form of skin metastases that exhibits extensive dermal and subcutaneous lymphatic invasion. This subcutaneous lymphatic invasion results in lymphoedema and diffuse skin erythema mimicking an infectious process, which differs from the typical form of cutaneous metastases such as nodules or masses. The incidences of cutaneous metastases in patients with metastatic cancer and with lung cancer are approximately 5% and 1.7%–3.1%, respectively; CLC accounts for approximately 5% of all cutaneous metastases. The most common histological feature observed in patients with lung cancer who develop CLC is adenocarcinoma, as in the present case. Cutaneous metastasis in lung cancer tends to occur in order in the anterior chest wall, back and abdomen. Cutaneous metastases are considered a late event in the evolution which suggests that CLC made the symptoms caused by SVC syndrome more intractable.

In the present case, when the patient presented with swelling and erythema of the neck and chest collateral veins and dyspnoea, CT revealed SVC stenosis. This disease course is typical of SVC syndrome, which was the main cause of the symptoms. SVC syndrome arises from the compression of thin-walled SVC by enlarged paratracheal lymph nodes, mostly caused by lung cancer. The common symptoms of SVC syndrome include neck swelling, dyspnoea, facial swelling, cough and dilated chest collateral veins. Contrast-enhanced CT may elucidate the cause and extent of venous obstruction in SVC syndrome. The initial treatment in emergent cases of SVC syndrome is endovascular stenting of the SVC to restore flow. SVC stenting is reported to improve symptoms of SVC syndrome within 1–3 days, and recurrence rarely occurs. In the present case, SVC blood flow remained despite its prominent stenosis, and symptoms improved for only a few hours. The rapid recurrence of symptoms is atypical for SVC syndrome and indicates that there were other causes that made the patient’s symptoms more intractable.

Figure 1 Photographs of the patient presenting with prominent oedema in the face and neck and with painless erythema and induration of the chest.

Figure 2 An axial image of contrast-enhanced CT acquired when the patient developed cervicofacial oedema. The image reveals stenosis of the superior vena cava.

Figure 3 An axial image of contrast-enhanced CT acquired on the day following balloon dilation. The image shows that the superior vena cava remained constricted.
of the majority of malignancies. Lung cancer is the quickest to metastasise to the skin (15.75 months) among solid tumours. The average survival time from the appearance of CLC in lung cancer (less than 3 months) is shorter than that from the appearance of cutaneous metastasis (3 to 5 months). The only cancer (less than 3 months) is shorter than that from the appearance of cutaneous metastasis (3 to 5 months). 3 7 12 The average survival time from the appearance of CLC in lung cancer and cervicofacial oedema develops erythema and induration atypical of SVC syndrome, we recommend a prompt skin biopsy for accurate diagnosis and for deciding on appropriate therapy.

**Learning points**

► Superior vena cava (SVC) syndrome is the major cause of cervicofacial oedema occurring in patients with malignancies, especially lung cancer.

► Cutaneous lymphangitis carcinomatosa (CLC), a rare form of cutaneous metastasis that causes lymphoedema and various erythemas, may also cause cervicofacial oedema similar to that observed in SVC syndrome.

► If the patients who developed cervicofacial oedema and SVC stenosis are refractory to the treatment of SVC syndrome, including endovascular stenting or radiotherapy, concurrence of CLC should be considered.

**REFERENCES**

1. Straka C, Ying J, Kong FM, et al. Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome. *Springerplus* 2016;5.

2. Marcovial I, Moreno A, Peyri J. Cutaneous infiltration by cancer. *J Am Acad Dermatol* 2007;57:577–80.

3. Damstra RJ, Jagtman EA, Steijlen PM. Cancer-related secondary lymphoedema due to cutaneous lymphangitis carcinomatosa: clinical presentations and review of literature. *Eur J Cancer Care* 2010;19:669–75.

4. Arfi A, Clavier A, Honart J, et al. Blue Lymphangitis of the Breast after Breast Cancer: Case Report. *Breast J* 2017;23:348–51.

5. Saeed S, Keehn CA, Morgan MB. Cutaneous metastasis: a clinical, pathological, and immunohistochemical appraisal. *J Cutan Pathol* 2004;31:419–30.

6. Palazia I, Angioli R, Cutigli F, et al. Skin relapse from cervical cancer. *Gynecol Oncol* 2002;87:155–6.

7. Hidaka T, Ishii Y, Kitamura S. Clinical features of skin metastasis from lung cancer. *Intern Med* 1996;35:459–62.
Reminder of important clinical lesson

8 Prat L, Chouaid C, Kettaneh A, et al. Cutaneous lymphangitis carcinomatosa in a patient with lung adenocarcinoma: case report and literature review. Lung Cancer 2013;79:91–3.
9 Lookingbill DP, Spangler N, Helm KF. Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. J Am Acad Dermatol 1993;29:229–36.
10 Kobayashi K, Nakachi I, Naoki K, et al. Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis. Clin Lung Cancer 2018.
11 Dhambri S, Zendah I, Ayadi-Kaddour A, et al. Cutaneous metastasis of lung carcinoma: a retrospective study of 12 cases. J Eur Acad Dermatol Venereol 2011;25:722–6.
12 Marcoal J, Penin RM, Lalijos R, et al. Cutaneous metastasis from lung cancer: retrospective analysis of 30 patients. Australas J Dermatol 2012;53:288–90.
13 Goss G, Tsai CM, Shepherd FA, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2016;17:1643–52.
14 Yang JC, Ahn MJ, Kim DW, et al. Osimertinib in pretreated T790M-Positive advanced non-small-cell lung cancer: AURA Study Phase II extension component. J Clin Oncol 2017;35:1288–96.
15 Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378:113–25.